A proof-of-concept nanorobot design could be
used to target cancer cells by their glucose consumption and deliver a drug
payload in response to tumour interaction. The development of nanorobots has been a
focus for researchers
due to their therapeutic and diagnostic potential. European Pharmaceutical Review’s Hannah Balfour
and Victoria Rees interviewed Professor Shlomi Dolev, Chair Professor and
founder of the Department of
Computer Science at Ben-Gurion University of
the Negev, Israel, to discuss his research into nanorobots
as a drug delivery system.
No comments:
Post a Comment